E
Arrowhead Pharmaceuticals, Inc.
ARWR
$17.67
$0.321.84%
E
Sell
3/14/2023Downgrade
Arrowhead Pharmaceuticals, Inc. (ARWR) was downgraded to E+ from D on 3/14/2023 due to a decline in the volatility index.
Arrowhead Pharmaceuticals, Inc. (ARWR) was downgraded to E+ from D on 3/14/2023 due to a decline in the volatility index.
D
Sell
2/23/2023Upgraded
Arrowhead Pharmaceuticals, Inc. (ARWR) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index, volatility index and valuation index.
Arrowhead Pharmaceuticals, Inc. (ARWR) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index, volatility index and valuation index.
D
Sell
2/8/2023Downgrade
Arrowhead Pharmaceuticals, Inc. (ARWR) was downgraded to D- from D on 2/8/2023 due to a noticeable decline in the solvency index and valuation index.
Arrowhead Pharmaceuticals, Inc. (ARWR) was downgraded to D- from D on 2/8/2023 due to a noticeable decline in the solvency index and valuation index.
D
Sell
12/21/2022Upgraded
Arrowhead Pharmaceuticals, Inc. (ARWR) was upgraded to D from D- on 12/21/2022 due to an increase in the volatility index, growth index and valuation index. Operating cash flow increased 0.26% from -$68.85M to -$68.67M.
Arrowhead Pharmaceuticals, Inc. (ARWR) was upgraded to D from D- on 12/21/2022 due to an increase in the volatility index, growth index and valuation index. Operating cash flow increased 0.26% from -$68.85M to -$68.67M.
D
Sell
11/21/2022Downgrade
Arrowhead Pharmaceuticals, Inc. (ARWR) was downgraded to D- from D on 11/21/2022 due to a substantial decline in the growth index, total return index and solvency index. EBIT declined 275.46% from $41.55M to -$72.91M, earnings per share declined from $0.41 to -$0.6813, and operating cash flow declined 209.75% from $62.73M to -$68.85M.
Arrowhead Pharmaceuticals, Inc. (ARWR) was downgraded to D- from D on 11/21/2022 due to a substantial decline in the growth index, total return index and solvency index. EBIT declined 275.46% from $41.55M to -$72.91M, earnings per share declined from $0.41 to -$0.6813, and operating cash flow declined 209.75% from $62.73M to -$68.85M.
D
Sell
5/16/2022Upgraded
Arrowhead Pharmaceuticals, Inc. (ARWR) was upgraded to D from E+ on 05/16/2022.
Arrowhead Pharmaceuticals, Inc. (ARWR) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
Arrowhead Pharmaceuticals, Inc. (ARWR) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index, valuation index and total return index.
Arrowhead Pharmaceuticals, Inc. (ARWR) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index, valuation index and total return index.
D
Sell
5/4/2022Upgraded
Arrowhead Pharmaceuticals, Inc. (ARWR) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
Arrowhead Pharmaceuticals, Inc. (ARWR) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
E
Sell
5/3/2022Downgrade
Arrowhead Pharmaceuticals, Inc. (ARWR) was downgraded to E+ from D- on 5/3/2022 due to a decline in the volatility index and total return index.
Arrowhead Pharmaceuticals, Inc. (ARWR) was downgraded to E+ from D- on 5/3/2022 due to a decline in the volatility index and total return index.
D
Sell
4/20/2022Downgrade
Arrowhead Pharmaceuticals, Inc. (ARWR) was downgraded to D- from D on 4/20/2022 due to a decline in the total return index, solvency index and volatility index. The quick ratio declined from 2.58 to 2.41.
Arrowhead Pharmaceuticals, Inc. (ARWR) was downgraded to D- from D on 4/20/2022 due to a decline in the total return index, solvency index and volatility index. The quick ratio declined from 2.58 to 2.41.
D
Sell
11/23/2021Upgraded
Arrowhead Pharmaceuticals, Inc. (ARWR) was upgraded to D from D- on 11/23/2021 due to an increase in the total return index, volatility index and valuation index.
Arrowhead Pharmaceuticals, Inc. (ARWR) was upgraded to D from D- on 11/23/2021 due to an increase in the total return index, volatility index and valuation index.
D
Sell
11/8/2021Downgrade
Arrowhead Pharmaceuticals, Inc. (ARWR) was downgraded to D- from D on 11/8/2021 due to a large decline in the efficiency index, total return index and solvency index. The quick ratio declined from 3.46 to 2.65, net income declined 11.58% from -$26.82M to -$29.92M, and total capital declined 1.77% from $469.35M to $461.03M.
Arrowhead Pharmaceuticals, Inc. (ARWR) was downgraded to D- from D on 11/8/2021 due to a large decline in the efficiency index, total return index and solvency index. The quick ratio declined from 3.46 to 2.65, net income declined 11.58% from -$26.82M to -$29.92M, and total capital declined 1.77% from $469.35M to $461.03M.
D
Sell
3/24/2021Downgrade
Arrowhead Pharmaceuticals, Inc. (ARWR) was downgraded to D from D+ on 3/24/2021 due to a large decline in the total return index.
Arrowhead Pharmaceuticals, Inc. (ARWR) was downgraded to D from D+ on 3/24/2021 due to a large decline in the total return index.
D
Sell
3/11/2021Downgrade
Arrowhead Pharmaceuticals, Inc. (ARWR) was downgraded to D+ from C- on 3/11/2021 due to a major decline in the total return index.
Arrowhead Pharmaceuticals, Inc. (ARWR) was downgraded to D+ from C- on 3/11/2021 due to a major decline in the total return index.
C
Hold
2/5/2021Upgraded
Arrowhead Pharmaceuticals, Inc. (ARWR) was upgraded to C- from D+ on 2/5/2021 due to a noticeable increase in the growth index, total return index and efficiency index. Total revenue increased 179.09% from $7.63M to $21.3M, earnings per share increased from -$0.4743 to -$0.2018, and net income increased 57.19% from -$48.43M to -$20.73M.
Arrowhead Pharmaceuticals, Inc. (ARWR) was upgraded to C- from D+ on 2/5/2021 due to a noticeable increase in the growth index, total return index and efficiency index. Total revenue increased 179.09% from $7.63M to $21.3M, earnings per share increased from -$0.4743 to -$0.2018, and net income increased 57.19% from -$48.43M to -$20.73M.
D
Sell
11/27/2020Downgrade
Arrowhead Pharmaceuticals, Inc. (ARWR) was downgraded to D+ from C- on 11/27/2020 due to a noticeable decline in the growth index, efficiency index and solvency index. Net income declined 255.83% from -$13.61M to -$48.43M, earnings per share declined from -$0.1336 to -$0.4743, and EBIT declined 214.31% from -$15.95M to -$50.12M.
Arrowhead Pharmaceuticals, Inc. (ARWR) was downgraded to D+ from C- on 11/27/2020 due to a noticeable decline in the growth index, efficiency index and solvency index. Net income declined 255.83% from -$13.61M to -$48.43M, earnings per share declined from -$0.1336 to -$0.4743, and EBIT declined 214.31% from -$15.95M to -$50.12M.
C
Hold
11/4/2020Upgraded
Arrowhead Pharmaceuticals, Inc. (ARWR) was upgraded to C- from D+ on 11/4/2020 due to an increase in the total return index.
Arrowhead Pharmaceuticals, Inc. (ARWR) was upgraded to C- from D+ on 11/4/2020 due to an increase in the total return index.
D
Sell
10/19/2020Downgrade
Arrowhead Pharmaceuticals, Inc. (ARWR) was downgraded to D+ from C- on 10/19/2020 due to a decline in the total return index and valuation index.
Arrowhead Pharmaceuticals, Inc. (ARWR) was downgraded to D+ from C- on 10/19/2020 due to a decline in the total return index and valuation index.
C
Hold
9/24/2020Upgraded
Arrowhead Pharmaceuticals, Inc. (ARWR) was upgraded to C- from D on 9/24/2020 due to a significant increase in the total return index.
Arrowhead Pharmaceuticals, Inc. (ARWR) was upgraded to C- from D on 9/24/2020 due to a significant increase in the total return index.
D
Sell
9/14/2020Downgrade
Arrowhead Pharmaceuticals, Inc. (ARWR) was downgraded to D from D+ on 9/14/2020 due to a substantial decline in the total return index.
Arrowhead Pharmaceuticals, Inc. (ARWR) was downgraded to D from D+ on 9/14/2020 due to a substantial decline in the total return index.
D
Sell
9/9/2020Downgrade
Arrowhead Pharmaceuticals, Inc. (ARWR) was downgraded to D+ from C- on 9/9/2020 due to a decline in the efficiency index and total return index.
Arrowhead Pharmaceuticals, Inc. (ARWR) was downgraded to D+ from C- on 9/9/2020 due to a decline in the efficiency index and total return index.
C
Hold
7/23/2020Upgraded
Arrowhead Pharmaceuticals, Inc. (ARWR) was upgraded to C- from D+ on 7/23/2020 due to a large increase in the total return index.
Arrowhead Pharmaceuticals, Inc. (ARWR) was upgraded to C- from D+ on 7/23/2020 due to a large increase in the total return index.
D
Sell
7/17/2020Upgraded
Arrowhead Pharmaceuticals, Inc. (ARWR) was upgraded to D+ from D on 7/17/2020 due to a large increase in the total return index and volatility index.
Arrowhead Pharmaceuticals, Inc. (ARWR) was upgraded to D+ from D on 7/17/2020 due to a large increase in the total return index and volatility index.
D
Sell
5/20/2020Downgrade
Arrowhead Pharmaceuticals, Inc. (ARWR) was downgraded to D from D+ on 5/20/2020 due to a large decline in the valuation index, growth index and efficiency index. Net income declined 641.88% from -$2.67M to -$19.84M, earnings per share declined from -$0.03 to -$0.2, and EBIT declined 358.22% from -$4.85M to -$22.24M.
Arrowhead Pharmaceuticals, Inc. (ARWR) was downgraded to D from D+ on 5/20/2020 due to a large decline in the valuation index, growth index and efficiency index. Net income declined 641.88% from -$2.67M to -$19.84M, earnings per share declined from -$0.03 to -$0.2, and EBIT declined 358.22% from -$4.85M to -$22.24M.
D
Sell
3/24/2020Downgrade
Arrowhead Pharmaceuticals, Inc. (ARWR) was downgraded to D+ from C- on 3/24/2020 due to a major decline in the total return index, growth index and volatility index. Operating cash flow declined 270.39% from $13.81M to -$23.53M, EBIT declined 150.36% from $9.64M to -$4.85M, and earnings per share declined from $0.112 to -$0.03.
Arrowhead Pharmaceuticals, Inc. (ARWR) was downgraded to D+ from C- on 3/24/2020 due to a major decline in the total return index, growth index and volatility index. Operating cash flow declined 270.39% from $13.81M to -$23.53M, EBIT declined 150.36% from $9.64M to -$4.85M, and earnings per share declined from $0.112 to -$0.03.
C
Hold
2/4/2020Downgrade
Arrowhead Pharmaceuticals, Inc. (ARWR) was downgraded to C- from C on 2/4/2020 due to a substantial decline in the total return index and growth index. EBIT declined 48.17% from $18.6M to $9.64M, and earnings per share declined from $0.21 to $0.112.
Arrowhead Pharmaceuticals, Inc. (ARWR) was downgraded to C- from C on 2/4/2020 due to a substantial decline in the total return index and growth index. EBIT declined 48.17% from $18.6M to $9.64M, and earnings per share declined from $0.21 to $0.112.
C
Hold
5/9/2019Upgraded
Arrowhead Pharmaceuticals, Inc. (ARWR) was upgraded to C from D on 5/9/2019 due to a significant increase in the total return index, efficiency index and volatility index. Net income increased 98.52% from $12.04M to $23.9M, and total capital increased 16.99% from $171.5M to $200.64M.
Arrowhead Pharmaceuticals, Inc. (ARWR) was upgraded to C from D on 5/9/2019 due to a significant increase in the total return index, efficiency index and volatility index. Net income increased 98.52% from $12.04M to $23.9M, and total capital increased 16.99% from $171.5M to $200.64M.
D
Sell
2/11/2019Upgraded
Arrowhead Pharmaceuticals, Inc. (ARWR) was upgraded to D from D- on 2/11/2019 due to a significant increase in the growth index, total return index and efficiency index. Operating cash flow increased 6,378.58% from -$2.68M to $168.28M, net income increased 211.86% from -$10.76M to $12.04M, and total revenue increased 207.93% from $11.26M to $34.66M.
Arrowhead Pharmaceuticals, Inc. (ARWR) was upgraded to D from D- on 2/11/2019 due to a significant increase in the growth index, total return index and efficiency index. Operating cash flow increased 6,378.58% from -$2.68M to $168.28M, net income increased 211.86% from -$10.76M to $12.04M, and total revenue increased 207.93% from $11.26M to $34.66M.
D
Sell
3/11/2016Downgrade
Arrowhead Research Corp. (ARWR) was downgraded to D- from D on 3/11/2016 due to a large decline in the volatility index, total return index and growth index. Operating cash flow declined 75.94% from -$12.02M to -$21.15M.
Arrowhead Research Corp. (ARWR) was downgraded to D- from D on 3/11/2016 due to a large decline in the volatility index, total return index and growth index. Operating cash flow declined 75.94% from -$12.02M to -$21.15M.
NASDAQ
03/06/2025 4:00PM Eastern
Quotes delayed
